Evaluation of ALK Rearrangement in Chinese Non-Small Cell Lung Cancer Using FISH, Immunohistochemistry, and Real-Time Quantitative RT- PCR on Paraffin-Embedded Tissues

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zhang, Yun Gang ^a   Jin, Mu Lan ^a   Li, Li ^a   Zhao, Hong Ying ^a   Zeng, Xuan ^b   Jiang, Lei ^a   Wei, Ping ^a   Diao, Xiao Li ^a   Li, Xue ^a   Cao, Qing ^a   Tian, Xin Xia ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALK ANTIBODY; CELL PROTEIN; PARAFFIN; PROTEIN ALK; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EML4 ALK GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE IDENTIFICATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMATOID CARCINOMA; SENSITIVITY AND SPECIFICITY; SIGNET RING CARCINOMA; TISSUE STRUCTURE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; YOUNG ADULT;

EID: 84878576680     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064821     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, et al. (2010) Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: A surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol 5: 23-28.
3. Giuseppe G, (2002) Targeted therapy in non-small cell lung cancer. Lung Cancer 38: S29-/S32.
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
5. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
6. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, et al. (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149.
7. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, et al. (1994) Fusion of a kinase gene ALK, to a nuclear gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284.
8. Chiarie R, Voena C, Ambrogio C, Piva R, Inghirami G, et al. (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8: 11-23.
9. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, (2008) et.al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68: 4971-4976.
10. Shaw AT, Yeap B Y, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253.
11. Solomon B, Varella-Garcia M, Camidge DR, (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4: 1450-1454.
12. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, et al. (2008) EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia10: 298-302.
13. Salido M, Pijuan L, Mart'i{dotless}nez-Avil'L, Galván AB, Cañadas I, et al. (2011) Increased ALK gene copy number and amplification are frequent in non small cell lung cancer. J Thorac Oncol 6: 21-27.
14. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 14: 6618-24.
15. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
16. Shaw AT, Solomon B, Kenudson MM, (2011) Crizotinib and testing for ALK. J Natl Compr Canc Netw 9: 1335-41.
17. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, et al. (2011) Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6: 459-465.
18. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, et al. (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thoracic Oncol 6: 466-472.
19. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16: 1561-1571.
20. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
21. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216-5223.
22. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008 14: 4275-4283.
23. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, et al. (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14: 439-449.